Eli Lilly acquires Organovo’s FXR program to advance IBD drug development
In a significant industry development, Eli Lilly and Company has acquired Organovo Holdings, Inc.’s FXR program, including its lead drug candidate FXR314, marking a major ... Read More
Ensho Therapeutics unveils new data on NSHO-101 as once-daily treatment for inflammatory bowel disease
Ensho Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing oral therapies for inflammatory diseases, has presented promising new data on NSHO-101, a novel once-daily ... Read More
Teva and Sanofi reveal promising Phase 2b data for duvakitug in ulcerative colitis and Crohn’s disease
Teva Pharmaceutical Industries Ltd. and Sanofi have unveiled encouraging new data from their Phase 2b RELIEVE UCCD trial, highlighting the potential of duvakitug, a novel ... Read More
AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition
In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics, a company at the forefront of peptide-based ... Read More
Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory ... Read More
Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated its prowess against placebo in the critical ... Read More
Eli Lilly completes $2.4bn acquisition of DICE Therapeutics
Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion ... Read More
Aeglea BioTherapeutics buys Spyre Therapeutics to revolutionize IBD treatment
Aeglea BioTherapeutics, a Nasdaq-listed company, has acquired Spyre Therapeutics, a private biotech company dedicated to advancing a promising pipeline of antibody therapeutics aimed at revolutionizing ... Read More
Lilly to acquire biopharma company DICE Therapeutics in $2.4bn deal
Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. ... Read More
Roivant Sciences, Pfizer create new business for inflammatory disease drug
Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605 (now RVT-3101) for inflammatory and fibrotic bowel ... Read More